Mode
Text Size
Log in / Sign up
N/A N=718 Randomized Screening

The Prevent Anal Cancer Palpation Study

Anal Cancer

Enrolled (actual)
718
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Practice Self-/Companion Exams (Behavioral); Control Arm (Behavioral)
Age
Adult, Older Adult · 25+ yrs
Sex
Male
Sponsor
Medical College of Wisconsin
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Concordance Between Self-examination and Clinician Examination
248; 246
PRIMARY
Concordance Between Self-examination and Clinician Examination
248; 246
PRIMARY
Concordance Between Companion Examination and Clinician Examination
19; 23
PRIMARY
Concordance Between Companion Examination and Clinician Examination
19; 23
PRIMARY
Number of Persons Who Practice the Self Examination
261; 255
PRIMARY
Number of Persons Who Practice the Companion Examination
20; 26
SECONDARY
Measuring the Difference Between Chicago and Houston Self-exam Concordance.
127; 139; 107; 108
SECONDARY
Measuring the Difference Between Chicago and Houston Companion Exam Concordance.
10; 6; 10; 16
SECONDARY
Waist Circumference for Persons Doing Self-examinations
96.1; 95.3
SECONDARY
Concordance Between Self-examination and Clinician Examination Stratified by Waist Circumference.
153; 174; 79; 71

Summary

Anal cancer is a common cancer among men having sex with men (MSM). We will investigate increasing detection of anal canal tumors through self- or partner-palpation of the anal canal among MSM and trans persons. This study in Houston and Chicago will recruit a sample of 100 couples (i.e., 200 partners) and 600 single persons (one-half HIV-positive), aged ≥ 25 years, who will be taught to perform an ASE or ACE. After performing the exam in private, the individual's ASE and partner's ACE will then be compared with a clinician's DARE. The assessment will be done at each of two visits, spaced 6-months apart. One-half of persons will be randomized to a practice condition to assess how practice affects accuracy and retention of exam procedure. Our hypothesis is that both ASE and ACE at visit 1 will have ≥70% sensitivity and ≥90% specificity using the clinician DARE as the gold standard at each of two visits.

Eligibility Criteria

Inclusion Criteria

  • Chicago or Houston Metro Residents
  • Persons who had sex with men in the prior five years
  • Cis-gendered men and transgender persons
  • Age: 25 years and over
  • Access to medical care for referral or treatment
  • Spanish or English speakers/readers
  • Individuals or couples
  • HIV+ or HIV-
  • Persons with or without comorbidities and physical disabilities

Exclusion Criteria

  • Unresolved health care provider's diagnosis of anal condyloma, hemorrhoids or anal cancer
  • DARE in the prior three months
  • Plans to move in the following six months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04090060). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search